Chronic myeloid leukaemia (CML) mortality statistics

Deaths

Deaths from chronic myeloid leukaemia, 2017-2019, UK.

Proportion of all deaths

Percentage chronic myeloid leukaemia contributes to total cancer deaths, 2017-2019, UK

Age

Peak rate of chronic myeloid leukaemia deaths, 2017-2019, UK

 

 

Trend over time

Change in chronic myeloid leukaemia mortality rates since the early 1970s, UK

Chronic myeloid leukaemia accounts for less than 1% of all cancer deaths in the UK (2017-2019).[1-4]

In females in the UK, chronic myeloid leukaemia accounts for less than 1% of all female cancer deaths. In males in the UK, it accounts for less than 1% of all male cancer deaths).

42% of chronic myeloid leukaemia deaths in the UK are in females, and 58% are in males (2017-2019).

Chronic myeloid leukaemia mortality rates (European age-standardised Open a glossary item (AS) rates) in the UK are significantly lower in females than in males (2017-2019).

Chronic myeloid leukaemia mortality rates (European age-standardised Open a glossary item (AS) rates) for persons are significantly lower than the UK average in Wales, and similar to the UK average in all other UK constituent countries.

For chronic myeloid leukaemia, mortality differences between countries largely reflect differences in incidence.

Chronic Myeloid Leukaemia (C92.1), Annual Average Number of Deaths, Crude and European Age-Standardised (AS) Mortality Rates per 100,000 Persons Population, UK, 2017-2019

  England Scotland Wales Northern Ireland UK
Female Deaths 83 7 3 0 94
Crude Rate 0.3 0.3 0.2 0.0 0.3
AS Rate 0.3 0.2 0.2 0.0 0.3
AS Rate - 95% LCL 0.2 0.1 0.1 N/A 0.2
AS Rate - 95% UCL 0.3 0.3 0.3 N/A 0.3
Male Deaths 114 9 4 4 131
Crude Rate 0.4 0.4 0.3 0.4 0.4
AS Rate 0.5 0.4 0.3 0.6 0.5
AS Rate - 95% LCL 0.4 0.3 0.1 0.2 0.4
AS Rate - 95% UCL 0.6 0.6 0.5 1.0 0.5
Persons Deaths 197 17 7 4 224
Crude Rate 0.4 0.3 0.2 0.2 0.3
AS Rate 0.4 0.3 0.2 0.2 0.4
AS Rate - 95% LCL 0.3 0.2 0.1 0.1 0.3
AS Rate - 95% UCL 0.4 0.4 0.3 0.4 0.4

95% LCL and 95% UCL are the 95% lower and upper confidence limits around the AS Rate Open a glossary item

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 2017-2019, C92.1.

Last reviewed:

Chronic myeloid leukaemia mortality is strongly related to age, with the highest mortality rates being in older people. In the UK in 2017-2019, on average each year around two-thirds of deaths (67%) were in people aged 75 and over.[1-4] This largely reflects higher incidence and lower survival for chronic myeloid leukaemia in older people.

Age-specific mortality rates rise steadily from around age 60-64 and more steeply from around age 75-79. The highest rates are in the 90+ age group for both females and males. Mortality rates are significantly lower in females than males in a number of (mainly older) age groups. The gap is widest at age 70 to 74, when the age-specific mortality rate is 2.1 times lower in females than males.

Chronic Myeloid Leukaemia (C92.1), Average Number of Deaths per Year and Age-Specific Mortality Rates per 100,000 Persons Population, UK, 2017-2019

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.

About this data

Data is for UK, 2017-2019, ICD-10 C92.1.

Last reviewed:

Chronic myeloid leukaemia age-standardised (AS) Open a glossary item rates for females and males combined decreased by 73% in the UK between 1971-1973 and 2017-2019.[1-4] The decrease was larger in females than in males.

For females, chronic myeloid leukaemia AS mortality rates in the UK decreased by 78% between 1971-1973 and 2017-2019. For males, chronic myeloid leukaemia AS mortality rates in the UK decreased by 71% between 1971-1973 and 2017-2019.

Over the last decade in the UK (between 2007-2009 and 2017-2019), chronic myeloid leukaemia AS mortality rates for females and males combined decreased by 15%. In females AS mortality rates decreased by 22%, and in males rates remained stable.

Chronic Myeloid Leukaemia (C92.1), European Age-Standardised Mortality Rates per 100,000 Persons Population, UK, 1971-2019

Chronic myeloid leukaemia mortality has fallen markedly since the early 2000s due to increasing use of tyrosine-kinase Inhibitors.[5]

Chronic myeloid leukaemia mortality rates have decreased overall in all broad age groups in females and males combined in the UK since the early 1970s.[1-4] Rates in 0-24s have decreased by 96% (though the absolute change is very small as rates are overall low in this age group), in 25-49s have decreased by 87%, in 50-59s have decreased by 92%, in 60-69s have decreased by 86%, in 70-79s have decreased by 76% and in 80+s have decreased by 36%.

Chronic Myeloid Leukaemia (C92.1), European Age-Standardised Mortality Rates per 100,000 Persons Population, By Age, UK, 1971-2019

References

  1. England and Wales data were accessed from Nomis mortality statistics by underlying cause, sex and age, November 2021: Nomis mortality statistics by underlying cause, sex and age.
  2. Scotland data were provided by ISD Scotland on request, November 2021. Similar data can be found here: http://www.isdscotland.org/Health-Topics/Cancer/Publications/index.asp(link is external).
  3. Northern Ireland data were provided by the Northern Ireland Cancer Registry on request, February 2022. Similar data can be found here: http://www.qub.ac.uk/research-centres/nicr/.
  4. Population data were published by the Office for National statistics, accessed July 2020. The data can be found here: Population estimates for the UK, England and Wales, Scotland and Northern Ireland, provisional: mid-2019.
  5. Trends in survival for Chronic Myeloid Leukaemia in England: 2001-10, Public Health England (Feb 2015)

About this data

Data is for UK, 1971-2019, C92.1.

Cancers in children and young people (aged 0-24) are best classified using a different system to cancers in adults, so the figures presented here may not correspond with those elsewhere.

Last reviewed:

There is evidence for an association between chronic myeloid leukaemia (CML) mortality and deprivation for males in England, but there is no evidence for an association for females.[1] England-wide data for 2007-2011 show European age-standardised Open a glossary item mortality rates are 33% higher for males living in the most deprived areas compared with the least deprived, but for females the rates are similar for those living in the least and most deprived areas.[1]

Chronic Myeloid Leukaemia (C92.1), European Age-Standardised Mortality Rates by Deprivation Quintile, England, 2007-2011

The estimated deprivation gradient in CML mortality for males and females living in the most and least deprived areas in England has not changed in the period 2002-2011.[1] It has been estimated that there would have been around 15 fewer cancer deaths each year in England during 2007-2011 if all people experienced the same mortality rates as the least deprived.[1]

References

  1. Cancer Research UK and National Cancer Intelligence Network. Cancer by deprivation in England: Incidence, 1996-2010, Mortality, 1997-2011. London: NCIN; 2014.

About this data

Data is for: England, 2007-2011, ICD-10 C92.1

Deprivation gradient statistics were calculated using mortality data for 2007-2011. The deprivation quintiles were calculated using the Income domain scores from the Index of Multiple Deprivation (IMD) from the following years: 2004, 2007 and 2010. Full details on the data and methodology can be found in the Cancer by Deprivation in England NCIN report.

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.